MRA Advisory Group Buys Shares of 2,545 Boston Scientific Corporation $BSX

Key Points

• MRA Advisory Group purchased 2,545 shares of Boston Scientific Corporation, valued at approximately $273,000, during the second quarter.
• Institutional investors and hedge funds now own 89.07% of Boston Scientific's stock, signaling strong confidence in the company's growth potential.
• Recent analyst reports have upgraded Boston Scientific with multiple firms raising their price targets, with a consensus target of $118.04 and a majority rating of "Buy."

MRA Advisory Group bought a new stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 2,545 shares of the medical equipment provider's stock, valued at approximately $273,000.

Several other hedge funds also recently made changes to their positions in BSX. GAMMA Investing LLC grew its stake in shares of Boston Scientific by 11,720.3% in the 1st quarter. GAMMA Investing LLC now owns 2,577,887 shares of the medical equipment provider's stock worth $260,057,000 after purchasing an additional 2,556,078 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Boston Scientific by 18.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 10,839,362 shares of the medical equipment provider's stock worth $968,172,000 after buying an additional 1,709,461 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Boston Scientific by 1.3% in the first quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider's stock worth $13,577,311,000 after buying an additional 1,697,945 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of Boston Scientific by 18.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider's stock worth $1,070,387,000 after buying an additional 1,664,108 shares during the period. Finally, Assenagon Asset Management S.A. boosted its holdings in shares of Boston Scientific by 161.9% in the first quarter. Assenagon Asset Management S.A. now owns 2,485,696 shares of the medical equipment provider's stock worth $250,757,000 after buying an additional 1,536,663 shares during the period. Institutional investors and hedge funds own 89.07% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on BSX shares. Wells Fargo & Company raised their price target on shares of Boston Scientific from $118.00 to $124.00 and gave the stock an "overweight" rating in a report on Thursday, July 24th. Leerink Partnrs upgraded shares of Boston Scientific to a "strong-buy" rating in a report on Monday, June 16th. Oppenheimer upgraded shares of Boston Scientific from a "market perform" rating to an "outperform" rating and raised their price target for the stock from $118.00 to $125.00 in a report on Monday, September 8th. Barclays raised their price target on shares of Boston Scientific from $125.00 to $133.00 and gave the stock an "overweight" rating in a report on Thursday, July 24th. Finally, Citigroup restated a "buy" rating and set a $125.00 price target (up from $119.00) on shares of Boston Scientific in a report on Thursday, May 22nd. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, Boston Scientific presently has a consensus rating of "Buy" and an average target price of $118.04.

Boston Scientific Trading Down 1.6%

Shares of BSX stock opened at $102.71 on Monday. The firm has a market capitalization of $152.19 billion, a P/E ratio of 61.14, a price-to-earnings-growth ratio of 2.47 and a beta of 0.65. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The firm's fifty day simple moving average is $104.86 and its 200 day simple moving average is $102.27. Boston Scientific Corporation has a 1 year low of $80.64 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same quarter in the previous year, the firm posted $0.62 EPS. The business's revenue for the quarter was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, sell-side analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Activity

In related news, Director Edward J. Ludwig sold 4,000 shares of the company's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the transaction, the director owned 18,479 shares in the company, valued at $1,959,328.37. This represents a 17.79% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company's stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $105.43, for a total transaction of $5,271,500.00. Following the transaction, the executive vice president owned 178,342 shares in the company, valued at approximately $18,802,597.06. This trade represents a 21.90% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 174,214 shares of company stock worth $18,397,457 over the last 90 days. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.